Adlai Nortye combines explosive revenue growth with severe cash burn, an unreliable analyst price target, and a business-quality score below the investment floor, leaving the growth narrative overshadowed by financial and data-quality concerns.
Thesis pillars
- Explosive Revenue Growth→Stable
- Severe Cash Burn→Stable
- Unreliable Analyst Target Data→Stable
- +2 more pillars — see the Why tab for full reasoning
Adlai Nortye Group Ltd. (ANL) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.97: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an... Read more
Sell if holding. Engine safety override at $13.97: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-09-03Recent Developments — Adlai Nortye Group Ltd.
Latest news
- NEWS Adlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M — benzinga Aug 14, 2026 positive
- NEWS Adlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I — benzinga Aug 3, 2026 positive
- NEWS Adlai Nortye Doses First Patient In The Intermittent Weekly Dosing Arm In Its Ongoing Phase 1 Clinical Trial Of AN9025, — benzinga Jul 16, 2026 positive
- NEWS Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower — benzinga Jun 30, 2026 neutral
Generated 2026-09-03T15:02:25Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Unprofitable operations — net margin -124.8%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.97: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 3.4:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $12.95. Score 5.1/10, moderate confidence.
Take-profit target: $20.61 (+48.0% upside). Prior stop was $12.95. Stop-loss: $12.95.
Quality below floor (3.4 < 4.0).
Adlai Nortye Group Ltd. trades at a P/E of N/A (forward -50.2). TrendMatrix value score: 5.4/10. Verdict: Sell.
9 analysts cover ANL with a consensus score of 4.2/5. Average price target: $24.
What does Adlai Nortye Group Ltd. do?Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer...
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in North Brunswick, New Jersey.